B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX^® Containers

BETHLEHEM, PA – March 24, 2025 – B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Cefazolin 3 g, the latest cefazolin dose addition to the DUPLEX^® Container portfolio.

Cefazolin is prescribed to prevent infections before, during or after surgery. B. Braun offers Cefazolin in 1 g, 2 g and now 3 g strength which is indicated for patients with body weight equal to or greater than 120 kg. The delivery of Cefazolin 3 g in the DUPLEX Container helps to ensure fast, simple and accurate administration with the added convenience of the right dose at the right time.

The DUPLEX Container is a ready-to-activate, two-compartment, flexible IV system that keeps pre-measured medication and diluent separate until ready to administer. Designed for easy stocking, DUPLEX Containers can be stored at room temperature with a minimum shelf life of 18 months and are compatible with automated medication dispensing systems.

“We are excited to add Cefazolin 3 g to our DUPLEX Container portfolio which allows us to address a previously unmet need for patients weighing 120 kg or more. DUPLEX Containers offer healthcare workers an easy-to-use solution that is activated at the bedside with no need for complicated reconstitution or messy thawing - saving time and labor for practitioners while reducing potential dosing errors,” said Shawn Brinson, Director of Marketing, Injectable Drugs.

Cefazolin 3 g in DUPLEX Containers keeps premeasured medication and diluent separate until the healthcare worker is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. A barcode referencing the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

For additional information, please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Contraindications:

Know hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillin or other beta-lactams.

About B. Braun

B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we’re uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®. The company employs 8,500 people at over 30 locations across North America.

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.